Val-Cit-PAB-MMAE

Cat. No.: HY-100374

CAS No.: 644981-35-1

Molecular Formula: $C_{58}H_{94}N_{10}O_{12}$

Molecular Weight: 1123.43

Target: Drug-Linker Conjugates for ADC

Pathway: Antibody-drug Conjugate/ADC Related

Storage: 4°C, stored under nitrogen

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (44.51 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.8901 mL	4.4507 mL	8.9013 mL
	5 mM	0.1780 mL	0.8901 mL	1.7803 mL
	10 mM	0.0890 mL	0.4451 mL	0.8901 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 5.5 mg/mL (4.90 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 5 mg/mL (4.45 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 5 mg/mL (4.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

IC_{50} & Target

Auristatin

CUSTOMER VALIDATION

- Patent. US20210093733A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA